kidney cancer drug test stopped after early success
(Reuters) – Bristol-Myers Squibb Co said on Thursday the success of its combination therapy to improve overall survival in kidney cancer patients... Read More
Tivozanib Approved in Europe for Kidney Cancer
The European Commission (EC) has approved tivozanib (Fotivda) for the treatment of patients with advanced renal cell carcinoma (RCC), according to AVEO,... Read More
MRI test could predict kidney cancer patients who may benefit from anti-vascular therapy
A magnetic resonance imaging (MRI) test that measures the volume of blood in tumours could help select which patients will benefit from... Read More
Mixed results for Opdivo/ Yervoy combo
A combination of Bristol-Myers Squibb’s Opdivo (nivolumab)and Yervoy (ipilimumab) has failed to significantly improve progression-free survival (PFS) compared to Pfizer’s Sutent in patients... Read More
Kidney Cancer Survey
SURVEY
Shorter Telomere Length Predicts Cancer in Patients With VHL
Shorter blood telomere length is a biomarker for tumor risk in patients with Von Hippel-Lindau (VHL) syndrome, according to an article published... Read More
microRNAs and the Future of Renal Cell Carcinoma Treatment
Researchers in America are zeroing in on microRNAs (miRNAs) circulating in the bloodstream as biomarkers for the detection and diagnosis of renal... Read More
Tests in USA on epacadostat and Keytruda combination
Incyte Corp. and Merck will work together in the USA to study the combination of epacadostat and Keytruda in people fighting several... Read More
Britain lagging behind Europe in diagnosing and treating cancer, report finds
The UK is trailing behind other European countries when it comes to diagnosing and treating cancer, a new report says. The study,... Read More
New treatment option: Cabozantinib is now available for use in the NHS for advanced kidney cancer patients
Kidney Cancer UK is delighted that National Institute for Health and Care Excellence (NICE) has recommended the drug cabozantinib (Cabometyx) be made... Read More
